Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
1.220
-0.110 (-8.27%)
At close: May 4, 2026, 4:00 PM EDT
1.266
+0.046 (3.77%)
Pre-market: May 5, 2026, 6:33 AM EDT
Quince Therapeutics Employees
Quince Therapeutics had 38 employees as of December 31, 2025. The number of employees increased by 2 or 5.56% compared to the previous year.
Employees
38
Change (1Y)
2
Growth (1Y)
5.56%
Revenue / Employee
n/a
Profits / Employee
-$2,209,974
Market Cap
19.89M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 38 | 2 | 5.56% | 38 | 0 |
| Dec 31, 2024 | 36 | 4 | 12.50% | 36 | 0 |
| Dec 31, 2023 | 32 | 11 | 52.38% | 32 | 0 |
| Dec 31, 2022 | 21 | -34 | -61.82% | 21 | 0 |
| Dec 31, 2021 | 55 | 17 | 44.74% | 55 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Citius Pharmaceuticals | 23 |
| OSR Holdings | 22 |
| SeaStar Medical Holding | 17 |
| NewcelX | 15 |
| Lipocine | 14 |
| Cocrystal Pharma | 10 |
| VYNE Therapeutics | 10 |
| Allarity Therapeutics | 8 |
QNCX News
- 5 weeks ago - Quince Therapeutics Settles Approximately $16.4 Million of Debt - Business Wire
- 2 months ago - Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks - Benzinga
- 2 months ago - Quince Therapeutics Stock Explodes 300% On Strategic Review - Benzinga
- 3 months ago - Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives - Business Wire
- 3 months ago - Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia - Business Wire
- 3 months ago - Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting - Business Wire
- 5 months ago - Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia - Business Wire
- 5 months ago - Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders - Business Wire